CD274 and neoplasm: Besides DC-CTL/CIK immunotherapy in this study, other immunotherapeutic agents also have made great progress in clinic, such as immune checkpoint inhibitor antibodies of PD-1/PD-L1 or CTLA-4, and chimeric antigen receptor-T cell (CAR-T) targeting specific tumor antigen.